fbpx

Exerpts from the publication

Methods:

In this double-blind, placebo-controlled, crossover trial, 29 patients with cancer-related anxiety and depression were randomly assigned and received treatment with single-dose psilocybin (0.3 mg/kg) or niacin, both in conjunction with psychotherapy. The primary outcomes were anxiety and depression assessed between groups prior to the crossover at 7 weeks.

Results:

Prior to the crossover, psilocybin produced immediate, substantial, and sustained improvements in anxiety and depression and led to decreases in cancer-related demoralization and hopelessness, improved spiritual wellbeing, and increased quality of life. At the 6.5-month follow-up, psilocybin was associated with enduring anxiolytic and anti-depressant effects (approximately 60–80% of participants continued with clinically significant reductions in depression or anxiety), sustained benefits in existential distress and quality of life, as well as improved attitudes towards death. The psilocybin-induced mystical experience mediated the therapeutic effect of psilocybin on anxiety and depression.

Conclusion:

In conjunction with psychotherapy, single moderate-dose psilocybin produced rapid, robust and enduring anxiolytic and anti-depressant effects in patients with cancer-related psychological distress.

Read more

Strategies to Prolong Ketamine’s Efficacy in Adults with Treatment-Resistant Depression

Eric P McMullen, Yena Lee, Orly Lipsitz, Leanna M W Lui, Maj Vinberg, Roger Ho, Nelson B Rodrigues, Joshua D Rosenblat, Bing Cao, Hartej Gill, Kayla M Teopiz, Danielle S Cha, Roger S McIntyre
April 2021

Ceremonial Ayahuasca in Amazonian Retreats—Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study

Simon G. D. Ruffell, Nige Netzband, WaiFung Tsang, Merlin Davies, Matthew Butler, James J. H. Rucker, Luís Fernando Tófoli, Emma Louise Dempster, Allan H. Young, Celia J. A. Morgan
June 2021

Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience

Martin K. Madsen, Dea S.Stenbæk, Albin Arvidsson, Sophia Armanda Maja R.Marstrand-Joergensen, Sys S. Johansen, Kristian Linnet, Brice Ozenne, Gitte M.Knudsen, Patrick M. Fisher
September 2021

Ayahuasca use and reported effects on depression and anxiety symptoms: An international cross-sectional study of 11,912 consumers

Jerome Sarris, Daniel Perkins, Lachlan Cribb, Violeta Schubert, Emerita Opaleye, José Carlos Bouso, Milan Scheidegger, Helena Aicher, Hana Simonova, Miroslav Horák, Nicole Leite Galvão-Coelho, David Castle, Luís FernandoTófoli
April 2021

Details